Kumaraguru Raja
Stock Analyst at Brookline Capital
(n/a)
# 4,898
Out of 4,900 analysts
15
Total ratings
7.69%
Success rate
-48.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PALI Palisade Bio | Maintains: Buy | $16 | $0.75 | +2,033.33% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.73 | +420.23% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $2.54 | +214.96% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $9.54 | +948.22% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $2.27 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.37 | +40,660.87% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $3.81 | +293.96% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $3.72 | +463.85% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $39.76 | +126.36% | 1 | Dec 9, 2022 | |
| VERU Veru Inc. | Maintains: Buy | $29 → $31 | $0.58 | +5,237.47% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,360 | $0.73 | +459,959.70% | 1 | Sep 21, 2021 |
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $0.75
Upside: +2,033.33%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.73
Upside: +420.23%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $2.54
Upside: +214.96%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $9.54
Upside: +948.22%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.27
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.37
Upside: +40,660.87%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $3.81
Upside: +293.96%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $3.72
Upside: +463.85%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $39.76
Upside: +126.36%
Veru Inc.
May 18, 2022
Maintains: Buy
Price Target: $29 → $31
Current: $0.58
Upside: +5,237.47%
Sep 21, 2021
Initiates: Buy
Price Target: $3,360
Current: $0.73
Upside: +459,959.70%